Malkani Dhiraj H 4
4 · Kiniksa Pharmaceuticals International, plc · Filed Jul 6, 2026
Research Summary
AI-generated summary of this filing
Kiniksa (KNSA) CSO Dhiraj Malkani Receives Equity Awards
What Happened
Dhiraj H. Malkani, Chief Strategy Officer of Kiniksa Pharmaceuticals International, received multiple equity awards on July 1, 2026. The filing reports six derivative awards (grants) totaling 103,459 units: 82,600; 14,000; 2,119; 2,188; 1,245; and 1,307. Each was reported at an acquisition price of $0.00 (i.e., awarded as compensation rather than purchased). These awards include a mix of stock-settled units and performance/option awards subject to vesting and performance conditions.
Key Details
- Transaction date: July 1, 2026; Form 4 filed July 6, 2026 (appears to be filed after the 2-business-day Form 4 deadline).
- Reported awards (all "A" = grant/acquisition at $0.00): 82,600; 14,000; 2,119; 2,188; 1,245; 1,307 — total 103,459 derivative units. Total reported cash paid = $0.00.
- Shares/units owned after transaction: Not specified in the filing.
- Notable footnotes (summary):
- F1: An option vests 25% after one year from vesting commencement (July 1, 2026), then monthly over 36 months.
- F2–F3: RSUs (each convertible to one Class A share) vest over four years with 25% vesting each year starting July 1, 2026.
- F4: One award is subject to an earnout (0–100%); the filing reflects 100% achievement.
- F5–F6: Performance Share Options (PSOs) vest upon FDA BLA submission (F5) or upon FDA approval for commercial sale (F6), subject to continued employment.
- F7–F9: Performance Share Units (PSUs) convert to Class A shares upon satisfaction of performance milestones tied to FDA submission (F8) or approval (F9).
- Filing timeliness: The Form 4 was filed July 6, 2026 for a July 1 transaction; this appears to miss the typical 2-business-day deadline and may be considered late.
Context
These were grants/awards (derivative instruments and contingent share units), not open-market purchases or sales. RSUs/PSUs represent contingent rights to receive shares upon vesting and/or achievement of specified milestones; PSOs are options that vest only if specified regulatory milestones for KPL-387 (recurrent pericarditis) are met. Because these are compensation awards with vesting and performance conditions, they reflect company compensation decisions rather than an executive buying or selling shares for personal investment.
Insider Transaction Report
- Award
Share Option
[F1]2026-07-01+82,600→ 0 totalExercise: $62.88Exp: 2036-06-30→ Class A Ordinary Share (82,600 underlying) - Award
Restricted Share Unit
[F2][F3]2026-07-01+14,000→ 0 total→ Class A Ordinary Share (14,000 underlying) - Award
Performance Share Option
[F4][F5]2026-07-01+2,119→ 0 totalExercise: $62.88Exp: 2036-06-30→ Class A Ordinary Share (2,119 underlying) - Award
Performance Share Option
[F4][F6]2026-07-01+2,188→ 0 totalExercise: $62.88Exp: 2036-06-30→ Class A Ordinary Share (2,188 underlying) - Award
Performance Share Unit
[F7][F4][F8]2026-07-01+1,245→ 0 total→ Class A Ordinary Share (1,245 underlying) - Award
Performance Share Unit
[F7][F4][F9]2026-07-01+1,307→ 0 total→ Class A Ordinary Share (1,307 underlying)
Footnotes (9)
- [F1]The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is July 1, 2026.
- [F2]Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
- [F3]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, July 1, 2026.
- [F4]The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.
- [F5]The Performance Share Options (PSO) shall vest and become exercisable, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.
- [F6]The PSOs shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.
- [F7]Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance
- [F8]The PSUs shall vest, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.
- [F9]The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.